Dr Sonia Mansukhani
Job title
Locum consultant medical oncologist
Qualifications
MBBS BMedSci PhD
GMC Number
7040142
Contact details
PA/secretary phone number: Angie Fisher - 020 7830 2169
PA/secretary email address: angie.fisher@nhs.net
Hospitals
Barnet Hospital
Related services
Biography
Dr Sonia Mansukhani is a consultant medical oncologist who completed her medical oncology training at the Royal Marsden Hospital in 2022. Her research interests include utilising circulating tumour DNA to detect evolution of chemotherapy resistance, translational research and developing novel combination therapeutics.
Publications
Real-world efficacy and safety of nivolumab in patients with previously treated metastatic renal cell carcinoma: A tertiary cancer centre experience: Mansukhani S, Suyanto S, Nocivin I, Broome L, Michael A, Pandha H. Submitted to Cancer Journal Dec 2021
Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumour DNA sequencing: Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, Matthews N, O’Leary B, Hulkki S, Gonzalez De Castro D, Patel A, Wotherspoon A, Okachi A, Rana I, Begum R, Davies MN, Powles T, von Loga K, Hubank M, Turner N, Watkins D, Chau I, Cunningham D, Lise S, Starling N, Gerlinger M. Clinical Chemistry 2018; 64 (11): 1626-1635
ICONIC: Peri-operative immune-chemotherapy in operable oesophageal and gastric cancer: Mansukhani S, Davidson M, Gillbanks A, Peckitt C, Musallam A, Begum R, Morganstein D, Wotherspoon A, Riddell A, Kinross J, Marchesi J, von Loga K, Allum W, Rao S, Watkins D, Chau I, Cunningham D, Starling N, Chaudry A, Gerlinger M. Journal of Clinical Oncology. 2018; 36 (15_suppl)
Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the PROSPECT-C biomarker trial: Khan KH, Woolston A, Spain G, Barber LJ, Patil Y, Griffiths B, GonzalezExposito R, Mansukhani S, Davies MN, Rao S, Watkins D, Sclafani F, Suntharanathan J, Peckitt C, Begum R, Rana I, Thomas J, Oates J, Bryant A, Wotherspoon A, Fotiadis N, Khan N, Guettler S, von Loga K, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M. Cancer Research. 2018; 78 (supp 13):4339-4339
Perioperative FLOT+ anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in: Davidson M, Mansukhani S, Starling N, Chau I, Watkins D, Cunningham D, Lazaro-Alcausi R, Griffiths B, Barber L, Morganstein D, Forster MD, Davies S, Begum R, Gillbanks A, Kalaitzaki E, Wotherspoon A, von Loga K, Chaudry A, Gerlinger M. Annals of Oncology. 2019; 30 (5_suppl)
Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer: Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jime’Nez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezeda S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger Ml. Cancer Cell. 2019; 36(1):35-50
Detecting and tracking circulating tumour DNA copy number profiles during first line chemotherapy in oesophagogastric adenocarcinoma: Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft SY, Rana I, Begum R, Assiotis I, Matthews N, Rao S, Watkins D, Chau I, Cunningham D, Starling N, Gerlinger M. Cancers; 2019;11(5). pii: E736
Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre: Chamberlain F, Farag S, Williams-Sharkey C, Collingwood C, Chen L, Mansukhani S, Engelmann B, Al-Muderis O, Chauhan D, Thway K, Fisher C, Jones R, Gennatas S, Benson, C. Clin Sarcoma Res. 2020
Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified? Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I. Clin Colorectal Cancer. 2016 Jun;15(2)